IFPMA welcomes WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. We need to capture the political momentum before and during the UN High-Level Meeting in September to bend the curve against NCDs in every country around the world.
In our call to action, we urge Member States to embrace innovation, mobilize investment, drive implementation and ensure accountability. Our industry remains a committed stakeholder in tackling NCDs. With over 9,600 NCD medicines in the R&D pipeline, we should be optimistic about the benefits that scientific innovation will bring to millions of patients. We will continue working with others to build solutions and contribute towards stronger health systems to improve the lives of people living with NCDs. A life-course approach to preventing and tackling NCDs is the only way to reduce the huge burden placed on patients and healthcare systems worldwide.